Document Detail

Darbepoetin alfa in systolic heart failure.
MedLine Citation:
PMID:  23902504     Owner:  NLM     Status:  In-Data-Review    
To the Editor: In their report on the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial, Swedberg et al. (March 28 issue)(1) conclude that the correction of anemia with the use of darbepoetin alfa in patients with heart failure does not reduce the rate of cardiovascular end points. This finding is in line with the results of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).(2) However, it may be difficult to generalize such results to all forms of anemia in heart failure, especially to anemia caused by iron deficiency. As found by Toblli et al. . . .
Related Documents :
12193154 - Myocardial abnormalities in hypertensive patients with normal and abnormal left ventric...
19390744 - Association of angiotensin-converting enzyme activity and polymorphism with echocardiog...
15010744 - Prevalence and significance of increased intraventricular velocities in healthy elderly...
15226274 - New gender-specific partition values for ecg criteria of left ventricular hypertrophy: ...
20050864 - Second lineage of heart forming region provides new understanding of conotruncal heart ...
8961204 - Outpatient cardiac rehabilitation: are the potential benefits being realised?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  369     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-08-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  487-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Weight loss in persons with serious mental illness.
Next Document:  Darbepoetin alfa in systolic heart failure.